Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion

Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest 2012-08, Vol.142 (2), p.394-400
Hauptverfasser: Fysh, Edward T.H., MBBS, Waterer, Grant W., PhD, Kendall, Peter A., MBBS, Bremner, Peter R., MBChB, Dina, Sharifa, RN, Geelhoed, Elizabeth, PhD, McCarney, Kate, RN, Morey, Sue, NP, Millward, Michael, MA, Musk, A.W. (Bill), MD, FCCP, Lee, Y.C. Gary, PhD, FCCP
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 400
container_issue 2
container_start_page 394
container_title Chest
container_volume 142
creator Fysh, Edward T.H., MBBS
Waterer, Grant W., PhD
Kendall, Peter A., MBBS
Bremner, Peter R., MBChB
Dina, Sharifa, RN
Geelhoed, Elizabeth, PhD
McCarney, Kate, RN
Morey, Sue, NP
Millward, Michael, MA
Musk, A.W. (Bill), MD, FCCP
Lee, Y.C. Gary, PhD, FCCP
description Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P < .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P < .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.
doi_str_mv 10.1378/chest.11-2657
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1095631499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0012369212604528</els_id><sourcerecordid>1095631499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</originalsourceid><addsrcrecordid>eNpFkU1r3DAQhkVoaTZpj7kWXwq5ONVIlmxdCmXztZCS0o-zkKVxotQrbyQ7Yf995eymPQ0Dz7zMPEPICdAz4HXz2d5jGs8ASiZFfUAWoDiUXFT8DVlQCqzkUrFDcpTSA809KPmOHDJWUakkXZB2Fdwz9r0Pd8X3Hqdo-mJpxnscMabiB7rJYrEKGzN6DGNxbrapuH3CuIMHh8mnohti8c30_i6YzLzGXHTdlPwQ3pO3nekTftjXY_L78uLX8rq8ub1aLb_elLaqqrEEKmonWsk56xTPpwnBHXSmlkI0jXEtk0ZIbKVUjbWsReY4CgdAK8uFYPyYnO5yN3F4nLIVvfbJ5ttMwGFKGqgSkkOlVEbLHWrjkFLETm-iX5u4zZCeteoXrRpAz1oz_3EfPbVrdP_oV48Z-LQHTLKm76IJ1qf_nGSM1vW845cdh1nEk8eobVbv88gf3GJ6GKYYsiMNOjFN9c_5g_MDgUlaCdbwvySLlW0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1095631499</pqid></control><display><type>article</type><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</creator><creatorcontrib>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><description>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P &lt; .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P &lt; .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.11-2657</identifier><identifier>PMID: 22406960</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: American College of Chest Physicians</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Cardiology. Vascular system ; Catheters, Indwelling ; Drainage - instrumentation ; Female ; Follow-Up Studies ; Humans ; Length of Stay ; Male ; Medical sciences ; Patient Preference ; Pilot Projects ; Pleural Effusion, Malignant - complications ; Pleural Effusion, Malignant - pathology ; Pleural Effusion, Malignant - therapy ; Pleurodesis ; Pneumology ; Prospective Studies ; Pulmonary/Respiratory ; Talc - administration &amp; dosage ; Treatment Outcome ; Tumors of the respiratory system and mediastinum</subject><ispartof>Chest, 2012-08, Vol.142 (2), p.394-400</ispartof><rights>The American College of Chest Physicians</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</citedby><cites>FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26220772$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22406960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fysh, Edward T.H., MBBS</creatorcontrib><creatorcontrib>Waterer, Grant W., PhD</creatorcontrib><creatorcontrib>Kendall, Peter A., MBBS</creatorcontrib><creatorcontrib>Bremner, Peter R., MBChB</creatorcontrib><creatorcontrib>Dina, Sharifa, RN</creatorcontrib><creatorcontrib>Geelhoed, Elizabeth, PhD</creatorcontrib><creatorcontrib>McCarney, Kate, RN</creatorcontrib><creatorcontrib>Morey, Sue, NP</creatorcontrib><creatorcontrib>Millward, Michael, MA</creatorcontrib><creatorcontrib>Musk, A.W. (Bill), MD, FCCP</creatorcontrib><creatorcontrib>Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><title>Chest</title><addtitle>Chest</addtitle><description>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P &lt; .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P &lt; .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Catheters, Indwelling</subject><subject>Drainage - instrumentation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patient Preference</subject><subject>Pilot Projects</subject><subject>Pleural Effusion, Malignant - complications</subject><subject>Pleural Effusion, Malignant - pathology</subject><subject>Pleural Effusion, Malignant - therapy</subject><subject>Pleurodesis</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Pulmonary/Respiratory</subject><subject>Talc - administration &amp; dosage</subject><subject>Treatment Outcome</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1r3DAQhkVoaTZpj7kWXwq5ONVIlmxdCmXztZCS0o-zkKVxotQrbyQ7Yf995eymPQ0Dz7zMPEPICdAz4HXz2d5jGs8ASiZFfUAWoDiUXFT8DVlQCqzkUrFDcpTSA809KPmOHDJWUakkXZB2Fdwz9r0Pd8X3Hqdo-mJpxnscMabiB7rJYrEKGzN6DGNxbrapuH3CuIMHh8mnohti8c30_i6YzLzGXHTdlPwQ3pO3nekTftjXY_L78uLX8rq8ub1aLb_elLaqqrEEKmonWsk56xTPpwnBHXSmlkI0jXEtk0ZIbKVUjbWsReY4CgdAK8uFYPyYnO5yN3F4nLIVvfbJ5ttMwGFKGqgSkkOlVEbLHWrjkFLETm-iX5u4zZCeteoXrRpAz1oz_3EfPbVrdP_oV48Z-LQHTLKm76IJ1qf_nGSM1vW845cdh1nEk8eobVbv88gf3GJ6GKYYsiMNOjFN9c_5g_MDgUlaCdbwvySLlW0</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Fysh, Edward T.H., MBBS</creator><creator>Waterer, Grant W., PhD</creator><creator>Kendall, Peter A., MBBS</creator><creator>Bremner, Peter R., MBChB</creator><creator>Dina, Sharifa, RN</creator><creator>Geelhoed, Elizabeth, PhD</creator><creator>McCarney, Kate, RN</creator><creator>Morey, Sue, NP</creator><creator>Millward, Michael, MA</creator><creator>Musk, A.W. (Bill), MD, FCCP</creator><creator>Lee, Y.C. Gary, PhD, FCCP</creator><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120801</creationdate><title>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</title><author>Fysh, Edward T.H., MBBS ; Waterer, Grant W., PhD ; Kendall, Peter A., MBBS ; Bremner, Peter R., MBChB ; Dina, Sharifa, RN ; Geelhoed, Elizabeth, PhD ; McCarney, Kate, RN ; Morey, Sue, NP ; Millward, Michael, MA ; Musk, A.W. (Bill), MD, FCCP ; Lee, Y.C. Gary, PhD, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-1057d5b6332f93378553d1fa765588adb26a56eb6698cc2be2d3e5d1104c35523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Catheters, Indwelling</topic><topic>Drainage - instrumentation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patient Preference</topic><topic>Pilot Projects</topic><topic>Pleural Effusion, Malignant - complications</topic><topic>Pleural Effusion, Malignant - pathology</topic><topic>Pleural Effusion, Malignant - therapy</topic><topic>Pleurodesis</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Pulmonary/Respiratory</topic><topic>Talc - administration &amp; dosage</topic><topic>Treatment Outcome</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fysh, Edward T.H., MBBS</creatorcontrib><creatorcontrib>Waterer, Grant W., PhD</creatorcontrib><creatorcontrib>Kendall, Peter A., MBBS</creatorcontrib><creatorcontrib>Bremner, Peter R., MBChB</creatorcontrib><creatorcontrib>Dina, Sharifa, RN</creatorcontrib><creatorcontrib>Geelhoed, Elizabeth, PhD</creatorcontrib><creatorcontrib>McCarney, Kate, RN</creatorcontrib><creatorcontrib>Morey, Sue, NP</creatorcontrib><creatorcontrib>Millward, Michael, MA</creatorcontrib><creatorcontrib>Musk, A.W. (Bill), MD, FCCP</creatorcontrib><creatorcontrib>Lee, Y.C. Gary, PhD, FCCP</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fysh, Edward T.H., MBBS</au><au>Waterer, Grant W., PhD</au><au>Kendall, Peter A., MBBS</au><au>Bremner, Peter R., MBChB</au><au>Dina, Sharifa, RN</au><au>Geelhoed, Elizabeth, PhD</au><au>McCarney, Kate, RN</au><au>Morey, Sue, NP</au><au>Millward, Michael, MA</au><au>Musk, A.W. (Bill), MD, FCCP</au><au>Lee, Y.C. Gary, PhD, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>142</volume><issue>2</issue><spage>394</spage><epage>400</epage><pages>394-400</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>Background Patients with malignant pleural effusion (MPE) have limited prognoses. They require long-lasting symptom relief with minimal hospitalization. Indwelling pleural catheters (IPCs) and talc pleurodesis are approved treatments for MPE. Establishing the implications of IPC and talc pleurodesis on subsequent hospital stay will influence patient choice of treatment. Therefore, our objective was to compare patients with MPE treated with IPC vs pleurodesis in terms of hospital bed days (from procedure to death or end of follow-up) and safety. Methods In this prospective, 12-month, multicenter study, patients with MPE were treated with IPC or talc pleurodesis, based on patient choice. Key end points were hospital bed days from procedure to death (total and effusion-related). Complications, including infection and protein depletion, were monitored longitudinally. Results One hundred sixty patients with MPE were recruited, and 65 required definitive fluid control; 34 chose IPCs and 31 pleurodesis. Total hospital bed days (from any causes) were significantly fewer in patients with IPCs (median, 6.5 days; interquartile range [IQR] = 3.75-13.0 vs pleurodesis, mean, 18.0; IQR, 8.0-26.0; P = .002). Effusion-related hospital bed days were significantly fewer with IPCs (median, 3.0 days; IQR, 1.8-8.3 vs pleurodesis, median, 10.0 days; IQR, 6.0-18.0; P &lt; .001). Patients with IPCs spent significantly fewer of their remaining days of life in hospital (8.0% vs 11.2%, P &lt; .001, χ2 = 28.25). Fewer patients with IPCs required further pleural procedures (13.5% vs 32.3% in pleurodesis group). There was no difference in rates of pleural infection ( P = .68) and protein ( P = .65) or albumin loss ( P = .22). More patients treated with IPC reported immediate (within 7 days) improvements in quality of life and dyspnea. Conclusions Patients treated with IPCs required significantly fewer days in hospital and fewer additional pleural procedures than those who received pleurodesis. Safety profiles and symptom control were comparable.</abstract><cop>Northbrook, IL</cop><pub>American College of Chest Physicians</pub><pmid>22406960</pmid><doi>10.1378/chest.11-2657</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-3692
ispartof Chest, 2012-08, Vol.142 (2), p.394-400
issn 0012-3692
1931-3543
language eng
recordid cdi_proquest_miscellaneous_1095631499
source MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Aged
Aged, 80 and over
Biological and medical sciences
Cardiology. Vascular system
Catheters, Indwelling
Drainage - instrumentation
Female
Follow-Up Studies
Humans
Length of Stay
Male
Medical sciences
Patient Preference
Pilot Projects
Pleural Effusion, Malignant - complications
Pleural Effusion, Malignant - pathology
Pleural Effusion, Malignant - therapy
Pleurodesis
Pneumology
Prospective Studies
Pulmonary/Respiratory
Talc - administration & dosage
Treatment Outcome
Tumors of the respiratory system and mediastinum
title Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Indwelling%20Pleural%20Catheters%20Reduce%20Inpatient%20Days%20Over%20Pleurodesis%20for%20Malignant%20Pleural%20Effusion&rft.jtitle=Chest&rft.au=Fysh,%20Edward%20T.H.,%20MBBS&rft.date=2012-08-01&rft.volume=142&rft.issue=2&rft.spage=394&rft.epage=400&rft.pages=394-400&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.11-2657&rft_dat=%3Cproquest_cross%3E1095631499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1095631499&rft_id=info:pmid/22406960&rft_els_id=1_s2_0_S0012369212604528&rfr_iscdi=true